Question 1

What is Johan Luthman?

Accepted Answer

Johan Luthman is a Person.

Question 2

How often does Johan Luthman appear in global news?

Accepted Answer

Tracked across 7 news events drawn from 45 articles.

Question 3

When was Johan Luthman first tracked by Ergen?

Accepted Answer

First tracked on Apr 13, 2026.

Question 4

When was Johan Luthman last mentioned in news?

Accepted Answer

Last active on Aug 19, 2026.

Question 5

What is Johan Luthman's current news sentiment?

Accepted Answer

Aggregate sentiment score: 13 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Johan Luthman in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 7 events.

Question 7

What is the most recent event involving Johan Luthman?

Accepted Answer

H. Lundbeck Asedebart Phase II Data (Jun 14, 2026, 6 articles).

Question 8

How did the "H. Lundbeck Asedebart Phase II Data" event impact Johan Luthman?

Accepted Answer

Johan Luthman, EVP and Head of Research & Development at Lundbeck, provided commentary on the promising Phase II data for asedebart, highlighting its potential as a novel therapeutic approach.

Question 9

How did the "H. Lundbeck A/S Presents Neurology Data" event impact Johan Luthman?

Accepted Answer

Johan Luthman, EVP and Head of Research & Development at Lundbeck, commented on the progress in neuroscience and Lundbeck's approach to drug development.

Question 10

How did the "H._Lundbeck asedebart Japan ODD" event impact Johan Luthman?

Accepted Answer

Johan Luthman, EVP and Head of Research and Development at Lundbeck, expressed satisfaction with the orphan drug designation, highlighting the company's commitment to rare diseases.

Question 11

How did the "H. Lundbeck receives South Korea migraine drug approval" event impact Johan Luthman?

Accepted Answer

Johan Luthman, EVP and Head of Research and Development at Lundbeck, commented on the significance of the approval for migraine patients in South Korea.

Question 12

How did the "FDA Fast Track for Lundbeck narcolepsy drug" event impact Johan Luthman?

Accepted Answer

Johan Luthman, Lundbeck's EVP R&D, commented on the Fast Track designation as an important milestone for the company's narcolepsy program.

Question 13

How did the "Lundbeck H1 2026 revenue growth" event impact Johan Luthman?

Accepted Answer

Retiring after seven years, transition of R&D leadership.

Question 14

How did the "Lundbeck completes DEEp OCEAN enrollment" event impact Johan Luthman?

Accepted Answer

Lundbeck's R&D head, announced the milestone and expressed confidence in the program.

Question 15

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.